| Ytd | 0.83% | |
| 1y | 277.33% |
| Open | 15.97 | Prev Close | 15.82 | Low | 15.55 | High | 16.07 | Mkt Cap | 1.33B |
| Vol | 53.01K | Avg Vol | 1.40M | EPS | -1.75 | P/E | -8.98 | Forward P/E | -8.47 |
| Beta | 1.59 | Short Ratio | 9.95 | Inst. Own | 113.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 20.39 | 200-d Avg | 18.33 | 1yr Est | 28.50 |
GLUE News
Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Co
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascu
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a ye
Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valua
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Co
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP re
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-st
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a wei
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vi
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendat
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Co
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a like
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-s
GLUE: 42% | Monte Rosa Therapeutics shares are trading higher after the company announced it will pr
On Monday, 369 companies set new 52-week lows.
On Wednesday, 345 companies set new 52-week lows.
Tuesday's session saw 286 companies set new 52-week lows.
On Monday, 147 stocks made new 52-week lows.
On Friday, 497 companies set new 52-week lows.
U.S. stocks closed higher on Thursday, with the Dow Jones jumping over 800 points. Here is the list
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Th
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
During Wednesday's morning trading, 400 companies set new 52-week lows.
Tuesday morning saw 454 companies set new 52-week lows.
During Friday's session, 445 companies made new 52-week lows.
Before 10 a.m. ET on Friday, 175 companies set new 52-week highs.
Before 10 a.m. ET on Monday, 201 companies set new 52-week highs.